Two women discussing efruxifermin, or EFX, in front of a whiteboard

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Jul 2025 | FROM AKERO THERAPEUTICS

A newly revealed signaling pathway may explain the conundrum of how FGF21 simultaneously increases insulin sensitivity and autophagy

Timothy Rolph, Morris J. Birnbaum Journal of Hepatology

May 2025 | FROM AKERO THERAPEUTICS

qFibrosis enables earlier detection of fibrosis response in Efruxifermin-treated patients with F2-F3 MASH in 96-week HARMONY study

Jörn M. Schattenberg, Dean Tai, Elaine Chng, Yukti Choudhury, Galvin Gan, Cynthia Behling, Pierre Bedossa, Doreen Chan, Jimmie Zhang, Erica Fong, Brittany de Temple, Matthew Minerva, Mark Burch, Kimberly Barrett, Reshma Shringarpure, Erik Tillman, Tim Rolph, Andrew Cheng, Kitty Yale, Mazen Noureddin EASL 2025

May 2025 | FROM AKERO THERAPEUTICS

Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, double-blind, placebo-controlled, phase 2b trial (SYMMETRY)

Mazen Noureddin, Mary E Rinella, Naga P Chalasani, Guy Neff, K Jean Lucas, Manuel E Rodriguez, Madhavi Rudraraju, Rashmee Patil, Cynthia Behling, Mark Burch, Doreen Chan, Erik J Tillman, Arian Zari BS, Brittany de Temple, Reshma Shringarpure, Meena Jain, Tim Rolph, Andrew Cheng, Kitty Yale EASL 2025

Jan 2025 | FROM AKERO THERAPEUTICS

Pleiotropic effects of FGF21 in liver, brain, and adipose tissue

Tim Rolph MASH-TAG 2025

Dec 2024 | FROM AKERO THERAPEUTICS

Improvement of liver fibrosis in efruxifermin-treated patients with MASH: correlation between conventional histopathology, AI-based digital histopathology, and non-invasive biomarkers of fibrosis

Erik J Tillman, Doreen Chan, Reshma Shringarpure, Yukti Choudhury, Elaine Chng, Dean Tai, Kitty Yale, Tim Rolph Keystone Symposia Fibrosis: Inflammation, Drivers, and Therapeutic Resolution

Nov 2024 | From Akero Therapeutics

Efruxifermin Significantly Improved Liver Fibrosis at Week 96 in the HARMONY Study Across Subgroups, and Improvements Were Associated With Changes in Biomarkers

Mazen Noureddin, Juan P Frias, Guy Neff, Gary A Abrams, K Jean Lucas, William Sanchez, Sudhanshu Gogia, Muhammed Y Sheikh, Cynthia Behling, Pierre Bedossa, Lan Shao, Doreen Chan, Erica Fong, Brittany de Temple, Matt Minerva, Kim Barrett, Reshma Shringarpure, Erik J Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale, Stephen A. Harrison The Liver Meeting 2024 (AASLD)

Nov 2024 | From Akero Therapeutics

Efruxifermin significantly reduced proportion of participants with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study

Mazen Noureddin, Cynthia Behling, Pierre Bedossa, Lan Shao, Elaine Chng, Yukti Choudhury, Dean Tai, Doreen Chan, Erica Fong, Brittany De Temple, Matt Minerva, Mark Burch, Kimberly Barrett, Reshma Shringarpure, Erik J Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale, Stephen A Harrison The Liver Meeting 2024 (AASLD)

Nov 2024 | From Akero Therapeutics

AI and Digital-Based Pathology Corroborate Reduction in Fibrosis Observed by Conventional Pathology with Efruxifermin Treatment of Patients with F2-F3 MASH in the HARMONY Study

Mazen Noureddin, Dean Tai, Elaine Chng, Yukti Choudhury, Cynthia Behling, Pierre Bedossa, Lan Shao, Doreen Chan, Jimmie Zhang, Erica Fong, Brittany de Temple, Matt Minerva, Mark Burch, Kim Barrett, Reshma Shringarpure, Erik J Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale, Stephen A Harrison The Liver Meeting 2024 (AASLD)

Close up of multichannel micropipette filling four small blue centrifuge tubes

We have developed a comprehensive clinical program to evaluate EFX as a potential treatment for MASH.

View Our Pipeline